Management of ALD Progressing to Cerebral ALD (CALD)
When X-linked adrenoleukodystrophy progresses to cerebral adrenoleukodystrophy, hematopoietic stem cell transplant (HSCT) is the only established treatment that stabilizes neurologic deterioration and increases survival, but only when performed in the earliest stages of cerebral disease. 1
Critical Timing for Intervention
The window for successful intervention is narrow and unforgiving. HSCT must be performed at the earliest stages of cerebral disease to be effective - once significant neurologic deterioration occurs, outcomes are poor. 2 This makes early detection through regular MRI surveillance absolutely essential for all males with ALD, particularly between ages 4-8 years when childhood cerebral ALD is most common. 1
Surveillance Protocol
For males diagnosed with ALD (whether by newborn screening or otherwise):
- Begin brain MRI screening by age 3 years and continue at regular intervals (typically every 6-12 months during high-risk periods)
- The core MRI protocol should include: 3D T1-weighted, spin-echo T2-weighted, 3D FLAIR, and diffusion-weighted imaging (DWI) 3
- Use DWI alongside the Loes score and post-contrast imaging to assess lesion progression 3
- Monitor for behavioral changes, declining school performance, gait abnormalities, vision/hearing problems - these are early warning signs 1
Treatment Algorithm
When cerebral lesions are detected:
- Immediate referral to a transplant center - do not delay
- HSCT is indicated for early-stage cerebral ALD (low Loes scores, minimal neurologic symptoms) 2, 4
- Gene therapy has shown promise in arresting disease progression in boys with childhood cerebral ALD and represents an alternative to traditional HSCT 5, 4
Critical Caveats
HSCT does NOT prevent or reverse adrenal insufficiency - this must be managed separately with lifelong glucocorticoid replacement. 1 The pathophysiology differs: cerebral disease has a progressive inflammatory component that HSCT can stabilize, while adrenal damage from VLCFA accumulation is already irreversible by the time of transplant. 1
For advanced cerebral ALD (significant neurologic deterioration, high Loes scores), HSCT outcomes are poor. Emerging data suggests potential roles for immunomodulatory agents (intravenous immunoglobulin, sirolimus, leriglitazone, mycophenolate) showing partial responses, though evidence remains limited. 6
Concurrent Adrenal Management
79-90% of boys with childhood cerebral ALD have adrenal insufficiency. 1 All patients must be screened for adrenal insufficiency at diagnosis and monitored regularly, with immediate glucocorticoid replacement if present. This is life-saving and prevents adrenal crisis, which can occur independently of neurologic status. 1
The key to improving morbidity and mortality in ALD-to-CALD progression is aggressive MRI surveillance starting early (by age 3) and immediate action when lesions appear - delays of even months can mean the difference between successful intervention and devastating neurologic decline.